• LAST PRICE
    0.1450
  • TODAY'S CHANGE (%)
    Trending Down-0.0100 (-6.4516%)
  • Bid / Lots
    0.1450/ 90
  • Ask / Lots
    0.1470/ 11
  • Open / Previous Close
    0.1550 / 0.1550
  • Day Range
    Low 0.1426
    High 0.1560
  • 52 Week Range
    Low 0.1315
    High 1.3100
  • Volume
    252,137
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Monday's close: 0.155
TimeVolumeVIRX
09:32 ET51220.155
09:35 ET2000.155
09:48 ET1000.151
09:55 ET98000.1509
09:57 ET83800.148
10:00 ET78330.1481
10:02 ET26000.1484
10:06 ET1000.1489
10:11 ET1000.1492
10:13 ET2000.1494
10:15 ET42310.1499
10:18 ET1000.1514
10:20 ET176000.1491
10:22 ET1000.1491
10:24 ET1000.1491
10:26 ET1000.1491
10:27 ET4000.1502
10:33 ET2260.1501
10:40 ET15000.1501
10:49 ET73460.1501
10:51 ET10550.1501
10:54 ET614020.1431
10:56 ET49000.1437
10:58 ET1000.1427
11:00 ET42480.1427
11:02 ET8000.1439
11:03 ET70010.1426
11:07 ET38000.1449
11:12 ET11950.1455
11:16 ET51910.147
11:18 ET7000.147
11:20 ET1000.1461
11:21 ET4400.1461
11:25 ET1000.1447
11:34 ET1000.1447
11:36 ET33020.1452
11:38 ET20000.1452
11:39 ET2000.1452
11:43 ET50450.1452
11:45 ET255620.1426
11:48 ET2000.1427
11:50 ET1000.1426
11:52 ET7560.1427
11:54 ET1000.1426
11:57 ET2000.1462
11:59 ET4370.1427
12:01 ET6000.1426
12:03 ET1000.1427
12:12 ET6550.1426
12:19 ET2000.1426
12:21 ET2000.1426
12:24 ET7000.1426
12:26 ET1000.1426
12:28 ET1000.1426
12:30 ET2000.1426
12:32 ET6560.1427
12:33 ET13000.143
12:35 ET17450.145
12:37 ET27350.148969
12:39 ET1000.145
12:42 ET3310.145
12:44 ET2000.143
12:46 ET1000.1426
12:48 ET5400.1494
12:53 ET5000.1426
12:55 ET1000.1427
01:04 ET8000.1494
01:06 ET5000.1426
01:22 ET6000.1426
01:24 ET8330.1426
01:26 ET1000.143
01:29 ET1000.1426
01:31 ET5000.1494
01:40 ET3000.146049
01:45 ET7450.145
01:47 ET27470.1465
01:49 ET5000.1455
01:51 ET1110.1492
01:54 ET1990.1455
01:56 ET6000.1475
01:58 ET1000.1475
02:00 ET2000.1455
02:02 ET1000.1494
02:03 ET6100.1465
02:05 ET1000.1465
02:09 ET1000.1465
02:14 ET8630.1465
02:16 ET4400.1465
02:18 ET1000.1465
02:21 ET1000.147
02:25 ET6000.1485
02:27 ET6130.1465
02:32 ET4000.1468
02:34 ET1000.1468
02:36 ET1020.1468
02:38 ET5660.1468
02:39 ET7010.1469
02:41 ET3730.1468
02:43 ET15490.1468
02:45 ET8770.1468
02:50 ET7850.1468
02:52 ET2000.1479
02:54 ET2280.1468
02:56 ET1430.1468
02:57 ET8590.1468
02:59 ET6070.1465
03:01 ET1000.1465
03:03 ET1000.1465
03:06 ET103320.145
03:08 ET21750.145
03:10 ET4470.145
03:12 ET3390.145
03:14 ET4920.145
03:15 ET4110.145
03:17 ET3550.145
03:19 ET4980.145
03:21 ET2000.145
03:24 ET69100.145
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesVIRX
Viracta Therapeutics Inc
6.3M
-0.1x
---
United StatesADIL
Adial Pharmaceuticals Inc
6.5M
-0.2x
---
United StatesGRI
GRI Bio Inc
6.2M
0.0x
---
United StatesCNSP
CNS Pharmaceuticals Inc
6.2M
0.0x
---
United StatesBCLI
Brainstorm Cell Therapeutics Inc
6.6M
-0.5x
---
United StatesRNAZ
Transcode Therapeutics Inc
6.6M
0.0x
---
As of 2024-11-26

Company Information

Viracta Therapeutics, Inc. is a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers, which impact patients worldwide. The Company’s lead product candidate is an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir (collectively, Nana-val). Nana-val is being evaluated in multiple ongoing clinical trials, including a pivotal, global, multicenter, open-label Phase II basket trial for the treatment of multiple subtypes of relapsed or refractory (R/R) Epstein-Barr virus-positive (EBV+) lymphoma (NAVAL-1), as well as a multinational, open-label Phase Ib/II clinical trial for the treatment of patients with recurrent or metastatic (R/M) EBV + nasopharyngeal carcinoma (NPC) and other advanced EBV + solid tumors. The Company is also pursuing the application of its Kick and Kill approach in other virus-related cancers.

Contact Information

Headquarters
2533 S COAST HWY 101, SUITE 210CARDIFF BY THE SEA, CA, United States 92007
Phone
858-400-8470
Fax
650-266-3501

Executives

Independent Chairman of the Board
Roger Pomerantz
President, Chief Executive Officer, Director
Mark Rothera
Chief Financial Officer
Michael Faerm
Senior Vice President - Finance
Melody Burcar
Chief Medical Officer
Darrel Cohen

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$6.3M
Revenue (TTM)
$0.00
Shares Outstanding
39.4M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.70
EPS
$-1.10
Book Value
$0.47
P/E Ratio
-0.1x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.